ChargePoint Technology expands smart monitoring technology into North America
Company's VERIFI smart monitoring hub allows production teams to manage and maintain their containment solution which, in turn, helps assure operator safety and sterility assurance related performance during pharmaceutical manufacturing processes.
Powder containment and sterile transfer solutions provider, ChargePoint Technology has achieved HazLoc (Hazardous Area) certification for VERIFI to further support customers in North America.
The HazLoc certification has been granted by the Canadian Standards Association (CSA) and will enable ChargePoint to expand its VERIFI smart monitoring hub into the North American market.
The VERIFI smart monitoring hub is a first-of-its-kind technology which monitors usage of ChargePoint’s split butterfly valve (SBV), used to provide containment during pharmaceutical manufacturing.
VERIFI continuously records valve-use providing data that allows production teams to manage and maintain their containment solution in a proactive and efficient manner. In turn, this helps assure operator safety and sterility assurance related performance during pharmaceutical manufacturing processes.
Chris Rombach, president at ChargePoint Technology commented: “Having seen the positive impact and excellent response to VERIFI in European markets, we are proud to bring VERIFI to North America. We can now give our customers more autonomy to improve operational performance and productivity, as well as helping them manage risk in their manufacturing processes.”
ChargePoint Technology has worked closely with CSA over the last two years to achieve the certification for Class 1 Zone 0 and Class II/III Zone 21, which was granted after an inspection of the company’s Liverpool, UK manufacturing headquarters in late 2018.
The company already holds Atmosphere Explosive (ATEX) and International Electro Commission (IEC) Explosive (Ex) certifications, allowing the use of VERIFI in hazardous environments in Europe.
Adam Bunyard, director of innovation and technology at ChargePoint Technology said: “Our customer base in the North American market is rapidly growing and we are excited to now be able to support existing and future customers with our unique smart monitoring technology.
“As the industry moves towards Industry 4.0, ChargePoint will remain at the forefront of contained transfer innovation, responding to the challenges of today and tomorrow.”
ChargePoint Technology’s solutions also include its AseptiSafe range of SBVs, designed to increase sterility assurance for ingredient and small component transfers in aseptic processing.
All of ChargePoint Technology’s transfer solutions are independently performance tested to the ISPE SMEPAC guidelines. The company works with select material handling solution partners globally to ensure an integrated high containment handling process is successfully achieved.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance